| Drug Name |
Lemborexant |
| Drug ID |
BADD_D02563 |
| Description |
Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to "switch-off" wake-promoting circuits.[A189006,A189030] Whereas historically popular pharmacologic treatments for insomnia (e.g. [zopiclone], [zolpidem], benzodiazepines) focus on enhancing sleep drive via modulation of GABA and melatonin receptors, lemborexant and other orexin antagonists (e.g. [suvorexant]) act to counteract inappropriate wakefulness.[A189006] This novel mechanism of action offers potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and potentially greater efficacy, and may signal the beginning of a new wave of treatment options for patients suffering from insomnia.[A189006] |
| Indications and Usage |
Lemborexant is indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.[L10863] |
| Marketing Status |
approved; investigational |
| ATC Code |
N05CM21 |
| DrugBank ID |
DB11951
|
| KEGG ID |
D11022
|
| MeSH ID |
C000634104
|
| PubChem ID |
56944144
|
| TTD Drug ID |
D0A7ZK
|
| NDC Product Code |
62856-410; 62856-455; 62856-405; 60510-405; 60510-410 |
| UNII |
0K5743G68X
|
| Synonyms |
lemborexant | dayvigo | (1R,2S)-2-(((2,4-dimethyl-5-pyrimidinyl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide | cyclopropanecarboxamide, 2-(((2,4-dimethyl-5-pyrimidinyl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)-, (1R,2S)- |
